| 7.64 0.15 (2%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.18  |
1-year : | 9.62 |
| Resists | First : | 7.86 |
Second : | 8.23 |
| Pivot price | 7.67 |
|||
| Supports | First : | 7.26 | Second : | 6.04 |
| MAs | MA(5) : | 7.42 | MA(20) : | 7.73 |
| MA(100) : | 8.36 |
MA(250) : | 8.99 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 24.1 |
D(3) : | 12.6 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 10.95 | Low : | 7.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GRFS ] has closed above bottom band by 47.0%. Bollinger Bands are 2.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.69 - 7.73 | 7.73 - 7.76 |
| Low: | 7.38 - 7.41 | 7.41 - 7.45 |
| Close: | 7.58 - 7.64 | 7.64 - 7.69 |
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Thu, 04 Jun 2026
Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst (NASDAQ:GRFS) - Seeking Alpha
Tue, 02 Jun 2026
Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo - Yahoo Finance
Mon, 01 Jun 2026
Grifols, S.A. (GRFS) Stock Analysis: Exploring a 38% Upside Potential Despite Recent Challenges - DirectorsTalk Interviews
Fri, 15 May 2026
Grifols (GRFS) schedules 2026 shareholders’ meeting with telematic attendance options - Stock Titan
Tue, 12 May 2026
Grifols, S.A. (NASDAQ:GRFS) Q1 2026 Earnings Call Transcript - Insider Monkey
Thu, 07 May 2026
Grifols Q1 2026 slides: biopharma growth offset by FX headwinds - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 681 (M) |
| Shares Float | 835 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 58.1 (%) |
| Shares Short | 5,970 (K) |
| Shares Short P.Month | 5,660 (K) |
| EPS | 0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.67 |
| Profit Margin | 5.5 % |
| Operating Margin | 16.4 % |
| Return on Assets (ttm) | 4.2 % |
| Return on Equity (ttm) | 6.1 % |
| Qtrly Rev. Growth | -4.9 % |
| Gross Profit (p.s.) | 4.18 |
| Sales Per Share | 10.93 |
| EBITDA (p.s.) | 2.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,020 (M) |
| Levered Free Cash Flow | 888 (M) |
| PE Ratio | 10.91 |
| PEG Ratio | 0.1 |
| Price to Book value | 1.63 |
| Price to Sales | 0.69 |
| Price to Cash Flow | 5.09 |
| Dividend | 0.17 |
| Forward Dividend | 0 |
| Dividend Yield | 2.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|